The small molecule API manufacturing market, valued at USD 197 billion in 2025, is projected to reach USD 204 billion in 2026 and USD 266 billion by 2035, representing a CAGR of 3.0% during the forecast period 2026 to 2035. In terms of type of manufacturers, the in-house manufacturers are likely to secure ~65% of the overall revenue share in 2026, due to the growing preference towards large, vertically integrated pharmaceutical companies. In March 2026, Cambrex announced the initial completion o...

The global cell encapsulation market, valued at USD 5.0 billion in 2025, is projected to reach USD 5.7 billion in 2026 and USD 15.8 billion by 2035, representing a CAGR of 12.0% during the forecast period 2026 to 2035. In April 2026, Atelerix signed a strategic partnership agreement with JH Health to expand the distribution and use of its proprietary non-cryogenic hydrogel encapsulation and cell preservation technology in the Middle East. In March 2026, researchers at MIT published findings on a...

The global viral vector and plasmid DNA manufacturing market, valued at USD 843 million in 2025, is projected to reach USD 937 million in 2026 and USD 2,161 million by 2035, with a CAGR of 9.73% during the forecast period 2026 to 2035. Presently, over 300 industry and non-industry players across the globe are actively involved so as to support the expanding pipeline of cell therapies, gene therapies, and vector-based vaccines, as per viral vectors and plasmid DNA manufacturing market report. In...

The global live cell encapsulation market, valued at USD 613 million in 2025, is projected to reach USD 642 million in 2026 and USD 1,787 million by 2035, representing a CAGR of 12.1% during the forecast period 2026 to 2035. In terms of therapeutic area, metabolic disorders are likely to hold the highest share (over 40%) of the future market share. Based on the type of payment, upfront payments capture the largest share (over 85%) of the current market. In terms of geographical regions, North Am...

The global non-viral transfection reagents market, valued at USD 0.79 billion in 2025, is projected to reach USD 0.89 billion in 2026 and USD 2.01 billion by 2035, representing a CAGR of 9.5% during the forecast period 2026 to 2035. In October 2025, MaxCyte signed a platform licensing agreement with Moonlight Bio, granting non-exclusive research, clinical, and commercial rights to Moonlight Bio’s Flow Electroporation technology and ExPERT platform for scalable development and manufacturing of...

The global biologics API market size, valued at USD 70.4 billion in 2025, is projected to reach USD 78.4 billion in 2026 and USD 153.8 billion by 2035, representing a CAGR of 8% during the forecast period, 2026 to 2035. Several large biopharmaceutical players, such as Novartis, Pfizer, Roche and Eli Lilly are supporting the active pharmaceutical ingredient manufacturing in their in-house API manufacturing facilities for the efficient production of various biologics. In the future, hybrid manufac...

The targeted protein degradation market is estimated to grow from USD 0.48 billion in 2024 to reach USD 1.00 billion in 2025 and USD 6.94 billion by 2035, representing a higher CAGR of 21% during the forecast period. In June 2025, SEED Therapeutics announced the appointment of Dr. Bill Desmarais as the Chief Financial Officer and Chief Business Officer, who previously served as Chief Business Officer at Alchemab Therapeutics. In May 2025, Kesmalea Therapeutics appointed Tim Clackson to its board...

The global biotherapeutics market, valued at USD 481 billion in 2025, is projected to reach USD 528 billion in 2026 and USD 1,048 billion by 2035, with a 7.9% CAGR during the forecast period 2026 to 2035. Biotherapeutics industry is anticipated to witness upward trajectory owing to the growing shift towards biologics for treating wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. The recent USFDA accelerated approval of AbbVie's Emrelis™ (telisotuzumab ved...

The global veterinary regenerative medicine market size, valued at USD 388 Million in 2025, is projected to reach USD 437 Million in 2026 and USD 1,189 Million by 2035, representing a CAGR of 11.8% during the forecast period. In terms of product, stem cell therapies is securing 53% of the market share driven by the widespread adoption of these therapies to treat wounds, damages tissues and chronic conditions. With regards to end user, the veterinary hospitals / clinics segment holds the highest...

The global regenerative medicine for spinal cord market size, valued at USD 16 million in 2025, is projected to reach USD 54 million in 2026 and USD 655 million by 2035, representing a CAGR of 32% during the forecast period, 2026 to 2035. The growth in the market is driven by strong scientific progress, expanding clinical trial activity, and increasing investment in advanced therapies such as stem cells and gene-based approaches. The global market for regenerative medicine for spinal cord injuri...

Researchers are currently focusing on the development of advanced stem cells, platelet-rich plasma (PRP), monoclonal antibodies (mAb), nutritional supplements, and pain management medication to improve motor function and comfort. In July 2025, Gallant (US) announced USD 18 million funding support to bring the first USFDA approved ready-to-use stem cell therapy to veterinary medicine to improve mobility in pets.

The cell sorting market, valued at USD 903 million in 2025 is expected to reach USD 1,078 million in 2026 and USD 3,085 million by 2035, representing a higher CAGR of 12.4% during the forecast period 2026 to 2035. Currently, the consumables and isolation kits segment dominates the market with ~60% market share and is likely to grow at a relatively higher CAGR, during the forecast period.

The cell line development market size valued at USD 1.46 billion in 2025, is project to reach USD 1.69 billion in 2026 and USD 4.50 billion by 2035, representing a higher CAGR of 11.5% during the forecast period 2026 to 2035. In terms of source of cell line, mammalian cells segment dominates the market with a 74% revenue share due to their critical role in producing complex proteins, monoclonal antibodies, and cell- and gene-based therapies. Notably, mid-sized players lead the market with a 39%...

The single use bioreactors market, valued at USD 4.32 billion in 2025, is projected to reach USD 4.81 billion in 2026 and USD 10.48 billion by 2035, with a CAGR of 9.03% during the forecast period, 2026 to 2035. The ongoing technological advancements focused on the development of improved versions of biosensors and single use bioreactor bags are likely to encourage the biopharmaceutical companies to adopt disposable bioreactors for continuous bioprocessing, representing a lucrative opportunity f...

The global DNA synthesis market, valued at USD 1.20 billion in 2025, is projected to reach USD 1.46 billion in 2026 and USD 8.63 billion by 2035, with a 22% CAGR during the forecast period 2026 to 2035. It is worth mentioning that a significant driver propelling the global DNA synthesis market is the increasing requirement for synthetic oligonucleotides such as DNA or RNA to develop therapies, including gene therapies, RNA-based therapies, and targeted therapies. Driven by the growing usage of...

The global gene switch market, valued at USD 795 million in 2025, is projected to reach USD 899 million in 2026 and USD 2,478 billion by 2035, with a 11.93% CAGR during the forecast period 2026 to 2035. Notably, in the past few years, close to 30 cell and gene therapy products have been approved by the US FDA. In addition, over 1,200 cell therapies are currently being evaluated across various clinical stages of development. However, despite various advantages, adverse events are associated with...

The global cell and gene therapy supply chain software market, valued at USD 312 million in 2025, is projected to reach USD 356 million in 2026 and USD 1,329 million by 2035, representing a CAGR of 15.8% during the forecast period 2026 to 2035. According to a report published by Novotech, it was anticipated that more than 12 novel cell and gene therapies would be approved by the end of 2023, highlighting lucrative opportunities for stakeholders in this market. Moreover, post-2018, over 40% of th...

The cell culture media market, valued at USD 9.0 billion in 2025, is projected to reach USD 9.7 billion in 2026 and USD 17.5 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. In July 2024, Merck KGaA invested EUR 6.6 million at Jiangsu, China site to expand the cell culture media manufacturing and production capabilities. In October 2024, Evonik established a global competence network for cell culture solutions in order to increase its offering of system solut...

With accelerated approval from the USFDA, several industrial players are taking strategic initiatives for technological innovations that help to explore more applications autologous cell therapies beyond cancer and autoimmune diseases. For instance, in November 2024, Nature Cell (a Korean biotechnology company) announced the success of autologous adipose stem cells that are delivered into spinal cavity of patient to treat Parkinson’s disease. This therapy has been developed by Japan Angel Stem...

The global allogeneic cell therapy market valued at USD 50.0 million in 2025, is projected to grow to USD 52.4 million in 2026 and USD 1,629.6 million by 2035, representing a CAGR of 46.5% during the forecast period 2026 to 2035. Over the past few years, a number of allogeneic cell therapies targeting a myriad of disorders, such as hematological malignancies and neurological disorders have received approval from various regulatory authorities, globally. In December 2022, the European Commission...